Merz Pharma GmbH & Co. KGaA is the parent company of the Merz Group, which manages three businesses Merz Aesthetics GmbH, Merz Therapeutics GmbH, and Merz Consumer Care GmbH.
It is the parent company of independent businesses in the fields of aesthetic medicine, therapeutic medicine (including for neurological movement disorders), and wellness and beauty products with its brands Tetesept and Merz Spezial.
Merz manages three production sites in Reinheim and Dessau (Germany) as well as in Racine County, Wisconsin (USA). In addition, the Group has its own sales offices in Brazil, France, Great Britain, Italy, Canada, South Korea, Mexico, Austria, Russia, Switzerland, Singapore, Spain, Taiwan, USA, etc., and operates in about 70 countries through cooperation and distribution partner.
The company's milestones:
- In 1908: The trained pharmacist and chemist Friedrich Merz set up his own pharmaceutical production in Frankfurt am Main.
- In 1911: Merz introduced the first topical contraceptive, Patentex, onto the market..
- In 1930: Establishment of new businesses in Berlin, Vienna, Zurich, London and Newark, USA.
- In 1953: Placentubex, an anti-wrinkle moisturizing cream that firms and rejuvenates the appearance of the skin, is presented by Friedrich Merz.
- In 1964: Friedrich Merz has developed Merz Spezial Dragees from 18 different active ingredients and a special yeast extract..
- In 1965: The tetesept brand established itself in the market. One of the first and most important products is the tetesept Cold Care Bath, the basis of which is formed by precious medicinal plants in the form of concentrated essential oils
- In 1968: Friedrich Merz develops the Placentubex Foaming Mask for the woman on the go.
- In 1970: Many patents and innovations recognized: Compounds for the treatment of Parkinson's disease, for the reduction of elevated blood lipids, for hepatic encephalopathy, and for the treatment of herpes.
- In 2002:Merz developed Memantine, the world's first active ingredient for the treatment of moderate to severe Alzheimer's dementia..
- In 2005: Merz brought a new generation of botulinum toxins into the market. At that time, the preparation was the only botulinum toxin type A (BoNT/A) without complexing foreign proteins and thus reduced the risk of antibody-mediated therapy failure.
- In 2010: Merz entered the field of medical aesthetics with the acquisition of the US-based dermal filler company BioForm Medical and its flagship product, RADIESSE.
- In 2013: Acquires Anteis, the company that manufactures dermal fillers and its brands Belotero, and Swiss skin care company Neocutis to strengthen its position in the field of cosmetic medicine.
- In 2014: Merz entered the non-invasive facelift medical device business with the acquisition of US company Ulthera for a sum close to USD 600 million.
- In 2015: Merz established Asia Pacific Headquarters in Singapore and subsidiary in Thailand.
- In 2016: Merz acquires US-based ON Light Sciences.
- In 2017: Signed a cooperation agreement with Teijin Limited, a technology-driven global group operating in the fields of materials, healthcare, and IT businesses, for the commercialization of Xeomi (incobotulinumtoxinA) for Japan..
- In 2020: Merz created a new business structure with 3 independent businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care.
According to merz.com, en.wikipedia.org
.png)
.png)
.png)
.jpg)
.jpg)
.jpg)
